is glp 1 semaglutide or tirzepatide & are transforming diabetes & obesity management. These GLP-1 receptor agonists offer benefits from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from semaglutide vs tirzepatide difference and

Since these drugs have been on the market for more than two decades, both Ferris and Alexander think theyve got a solid track record

In one trial, participants taking 5 mg lost 15% of their body weight, those taking 10 mg lost 19.5%, and those taking 15 mg lost 20.9% after 72 weeks

Cardiorenal syndrome

Science 296 , 490494 (2002)

Changes in HbA1c levels from baseline to week 26 was the primary efficacy endpoint measure by the research team while the secondary efficacy endpoints measure at week 26 included the proportion of patients achieving HbA1c target levels of less than 7.0%

It has been mentioned many times that current research, both pre-clinical and clinical, is focused around exendin-4 ligands